Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.89 |
| ▸ | CHAT | P28329 | 2/20 | 0.85 |
| ▸ | EP300 | Q09472 | 3/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.84 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.84 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16983169 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL59684 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL21874989 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL25996812 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28097736 | 1.00 | NAA50 (0.89) | NAA50CHATEP300AURKAKAT5 | |
| Lithium SCHEMBL29390807 | 0.99 | NAA50 (0.88) | NAA50CHATEP300AURKAKAT5 | |
| Lithium SCHEMBL18249414 | 0.99 | NAA50 (0.88) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28324180 | 0.98 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| Isobutyraldehyde SCHEMBL28444156 | 0.97 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28487648 | 0.97 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009249-A1 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-01-11 | — | — | US | claimed |
| WO-2022266480-A1 | METHODS OF PREDICTING LIVER FAT CONTENT AND USES THEREOF | AXCELLA HEALTH INC. (US) | 2022-12-22 | — | — | WO | claimed |
| EP-3301182-B1 | Fermentative production of four carbon alcohols | BUTAMAX TM ADVANCED BIOFUELS (US) | 2020-03-18 | — | — | EP | claimed |
| EP-1948814-B1 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | BUTAMAX TM ADVANCED BIOFUELS (US) | 2018-11-21 | — | — | EP | claimed |
| EP-2848694-B1 | METHOD FOR PRODUCING METHACRYLIC ACID ESTER | MITSUBISHI CHEM CORP (JP) | 2018-08-01 | — | — | EP | claimed |
| EP-2614138-B1 | INTEGRATION OF A POLYNUCLEOTIDE ENCODING A POLYPEPTIDE THAT CATALYZES PYRUVATE TO ACETOLACTATE CONVERSION | BUTAMAX (TM) ADVANCED BIOFUELS LLC (US) | 2017-08-30 | — | — | EP | claimed |
| EP-3008194-A2 | METHOD FOR PRODUCING ORGANIC COMPOSITIONS FROM OXYHYDROGEN AND CO2 VIA ACETOACETYL-COA AS INTERMEDIATE PRODUCT | Evonik Degussa GmbH (DE) | 2016-04-20 | — | — | EP | claimed |
| WO-2014198560-A2 | METHOD FOR PRODUCING ORGANIC COMPOSITIONS FROM OXYHYDROGEN AND CO2 VIA ACETOACETYL-COA AS INTERMEDIATE PRODUCT | EVONIK INDUSTRIES AG (DE) | 2014-12-18 | — | — | WO | claimed |
| EP-2813575-A1 | Method for the preparation of organic compounds from oxyhydrogen and CO2 using acetoacetyl-CoA as an intermediate product | Evonik Industries AG (DE) | 2014-12-17 | — | — | EP | claimed |
| CN-103080298-A | Integration of polynucleotides encoding polypeptides that catalyze the conversion of pyruvate to acetolactate | BUTAMAX ADVANCED BIOFUELS LLC | 2013-05-01 | — | — | CN | claimed |
| EP-1761628-A2 | NOVEL GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2006000343-A2 | NOVEL GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-01-05 | — | — | WO | claimed |
| WO-2026106979-A1 | PROCESSES AND SYSTEMS FOR FERMENTATIVE ALCOHOL PRODUCTION AND RECOVERY | GEVO, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132429-A1 | PROCESSES AND SYSTEMS FOR FERMENTATIVE ALCOHOL PRODUCTION AND RECOVERY | GEVO INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622876-B2 | Methods of suppressing delivery of exosomes to liver and spleen | LONZA SALES AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000029596-A1 | PHOSPHONATE METABOLIZING PLANTS | MONSANTO COMPANY (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132429-A1 | PROCESSES AND SYSTEMS FOR FERMENTATIVE ALCOHOL PRODUCTION AND RECOVERY | GK, ADH1C, ADH5 | NAA50 1298/4885CHAT 2608/4885EP300 1732/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | NAA50 1893/4885CHAT 1108/4885EP300 2771/4885 |
| US-12622876-B2 | Methods of suppressing delivery of exosomes to liver and spleen | EXOSC10, EXOSC5, EXOSC4 | NAA50 4812/4885CHAT 2841/4885EP300 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.